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Gruvberger et al. postulate, in their commentary [1] pub-
lished in this issue of Breast Cancer Research, that our
“prognostic gene set may not be broadly applicable to
other breast tumor cohorts”, and they suggest that “it may
be important to define prognostic expression profiles sep-
arately in estrogen receptor (ER) positive and negative
tumors”. This is based on two observations derived from
our gene expression profiling data in breast cancer [2]: the
overlap between reporter genes for prognosis and ER
status, and Gruvberger et al.’s inability to confirm the
prognosis prediction using a nonoptimal selection of 58 of
our 231 prognosis reporter genes.
The overlap between our prognosis reporter genes and
the ER status genes is certainly very large, mainly because
~10% of all genes on our microarray contain information
on the ER status (2460 out of 24,479). However, the
overlap between the 70 optimal prognosis genes and the
550 optimal ER status genes is only 17% (12 out of 70).
We therefore believe that there is a different subset of
genes that reports prognosis as compared with ER status.
Our prognosis classifier strongly predicts the risk of
distant metastases (odds ratio = 15, 95% confidence
interval = 4–56, P < 0.0001). Adjusted for associations
with known clinical prognosticators, including ER status,
in a multivariable analysis, this odds ratio slightly increases
to 18 (95% confidence interval = 3.3–94, P = 0.0002)
[2]. This indicates that the predictive capacity of our prog-
nosis classifier cannot be explained by its association
with, among other factors, ER status as suggested.
There are a few points of concern relating to Gruvberger
et al.’s inability to develop an outcome classifier on their
data set. It should be pointed out that the prognosis signa-
ture is subtle both in the number of genes and the magni-
tude of differential regulation as compared with the ER
status signature. The microarray platform sensitivity and
reproducibility is a key issue in generating high quality
data that ultimately determine the power of discovery. The
reproducibility of our platform is clearly demonstrated by
the uniform patterns related to ER status (Fig. 3b in [2]) as
compared with the ER status expression patterns pub-
lished by Gruvberger et al. (Fig. 2b in [3]). Our experi-
ences with cDNA arrays and oligonucleotide arrays
showed that the cDNA arrays are less sensitive in detect-
ing small differential regulations because of the high
chance of nonspecific binding.
Another point concerns the reference sample used in the
two-color assay and its effect on the sensitivity. A nearby
reference (a tumor sample pool in our case) makes the
differences between the samples easily detectable,
whereas a distant reference (one cell line [1]) makes this
harder to detect since the fluctuations of the large offset
interferes with the measurement of small differential
signals. Moreover, we always repeat the same measure-
ment twice in fluor-reversal pairs to minimise the potential
labeling biases.
It is possible that the aforementioned reasons and the fact
that most of our 70 optimal genes were not on their array
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prevented Gruvberger et al. from revealing the prognosis
signature.
Finally, it is of importance to note that we derived our
prognosis classifier from breast cancer patients of whom
the majority (93%) did not receive adjuvant systemic
therapy, whereas all Gruvberger et al.’s patients received
adjuvant tamoxifen treatment. So, a relatively better
outcome (approximately 30%) can be expected within
Gruvberger et al.’s ER-positive subgroup because of the
tamoxifen treatment. The predictive power of our progno-
sis reporters may be reduced in an adjuvantly treated
patient group.
A confirmation on a large unselected ‘cohort’ of breast
cancer patients is required to validate our findings. We
have recently completed DNA microarray analyses on a
cohort of 295 breast cancer samples. The results of this
will be published in the near future.
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